Guardant Health, Inc. (GH, Financial), a prominent player in the liquid biopsy field, experienced a significant share price drop of 5.00%. Currently trading at $20.54 with a trading volume of 790,168 shares, the stock shows a turnover rate of 0.64% and a price volatility of 4.53%.
Financial reports indicate that Guardant Health posted a revenue of $177 million, but faced a net loss of $103 million, translating to an earnings per share (EPS) of -$0.84. The company's gross profit stood at $105 million, with a negative price-to-earnings (P/E) ratio of -5.00.
Investor sentiment remains positive, with 92% of 24 rating institutions recommending a buy, 4% suggesting hold, and another 4% advising to sell. Within the life sciences sector, where Guardant Health operates, the overall increase was 0.88%. Some related stocks like Prophase Labs, Inc., Twist Bioscience Corporation, and Burning Rock Biotech Limited saw notable gains.
Guardant Health is headquartered in Redwood City, California, and is known for its liquid cancer diagnostics used both clinically and in research. Their offerings include Guardant360 LDT for late-stage cancer treatment options and Guardant360 CDx, FDA-approved for multiple targeted therapies. Additional products like Guardant OMNI, Reveal, and Shield are tailored for various oncological and diagnostic applications, alongside regulatory and clinical trial consulting services.
